Why Milestone Pharmaceuticals (MIST) Shares Are Trading Higher Premarket Today - Milestone Pharmaceuticals (NASDAQ:MIST)

Milestone Pharmaceuticals Inc MIST announced topline efficacy and safety data from the Phase 3 RAPID clinical trial of etripamil for paroxysmal supraventricular tachycardia (PSVT), a type of abnormal heart rhythm (arrhythmia).
The RAPID trial achieved its primary endpoint, with patients taking etripamil demonstrating a highly statistically significant and clinically meaningful difference in time to PSVT conversion compared to placebo.
A statistically significantly greater proportion of patients who took etripamil converted within thirty minutes compared to placebo (64.3% vs. 31.2%).
In addition, the median time to conversion for patients in RAPID who took etripamil was three times faster thaan for patients who took the placebo.
The safety and tolerability data from the RAPID trial continue to support the potential self-use of etripamil, with findings consistent with those observed in prior trials.
Analyses of pooled data from the NODE-301 and RAPID trials show that etripamil treatment provided a statistically significant reduction in the use of additional medical interventions and a statistically significant reduction in visits to the emergency department.
The Company believes results from the RAPID trial and data from the already completed NODE-301 trial could fulfill the efficacy requirement for FDA marketing application submission, expected in mid-2023.
Price Action: MIST shares are up 21.30% at $10.30 during the premarket session on the last check Monday.

Milestone Pharma Stock Surges After Successful Trial For Abnormal Heart Rhythm Candidate